about
Genetically distinct subsets within ANCA-associated vasculitisWhole blood cytokine attenuation by cholinergic agonists ex vivo and relationship to vagus nerve activity in rheumatoid arthritis.High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestationsPlasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysisCholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis.Renal expression and serum levels of high mobility group box 1 protein in lupus nephritisHigh Mobility Group Box Protein-1 correlates with renal function in chronic kidney disease (CKD).Interferon therapy for HCV-associated glomerulonephritis: meta-analysis of controlled trials.Macrophage migration inhibitory factor (MIF) and thyroid hormone alterations in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review.High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.Interferon/pegylated interferon and ribavirin in HCV-associated kidney disease with or without cryoglobulinemia.Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients.Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial activation.Rituximab for minimal change disease in adults: long-term follow-up.Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis.The influence of hepatitis C and iron replacement therapy on plasma pentosidine levels in haemodialysis patients.Serum retinol-binding protein concentration and its association with components of the uremic metabolic syndrome in nondiabetic patients with chronic kidney disease stage 5.Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia.Pegylated interferon and ribavirin in haemodialysis patients.Interferon and ribavirin therapy in dialysis patients with chronic hepatitis C.Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.Treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia—anti-viral therapy vs rituximabEndorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statementRenal-limited vasculitis in children: a single-center retrospective long-term follow-up analysisGamma glutamyltranspeptidase activity and viral hepatitis in dialysis populationHepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantationRituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patientsEffect of Treatment on Damage and Hospitalization in Elderly Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis
P50
Q28943363-53D33481-32B3-49FE-8536-90D2853E3234Q34119021-C16EFF45-9142-47D1-8C70-57F536CACDD8Q34500661-1F9B0BB0-E531-4B53-819D-8B690C247032Q34708735-FD46EB84-00A4-4CFD-A3AB-ADA0FB6324F8Q35856595-34AF61DE-A000-45B2-8830-88B1E48FC19DQ36085036-6EAC5F28-EFFC-43DD-94E9-59B191BC896EQ36481939-5BEEFEA9-2244-4EB4-9AC7-E843128245B7Q36785048-75ABCCEC-0EEA-4EDF-8EE3-66ED8A4E265AQ36885682-553EC630-88EF-43CA-96F3-ECF8D853C51FQ38206050-AD4B9A28-5310-40F0-8652-34179E2CFD8CQ42990082-01045ADF-FE7A-4A23-B672-65B0E3B01E50Q42997063-6E6536C3-DC12-441B-AD61-9E567A30E4DEQ42999766-81742C6F-14AB-4D21-A290-DC4C7B01BB60Q43230114-017F9006-97D8-4D85-AE60-85D2CC715974Q44197548-F0BBC8F6-3954-4166-825B-40E224BC0617Q44228676-DEC30E73-31F1-4558-B466-032314FE420FQ45091865-D7491222-E550-44E8-9771-23A1DD57EEF0Q46235370-D20226D7-C111-4D31-B89D-DABD25A57CD3Q48524719-C79C5FCE-9297-47A7-B508-1802B5140C74Q50576867-51EA40CD-48A3-42DB-8814-7295D7E14C9CQ50585601-B93844EF-510B-4C73-99A5-689C2029A000Q55055285-2BE03F2A-D138-4AD8-8E88-E486AF2930B9Q58621818-096B34FF-4060-4426-9F64-2F646CFFEF4FQ58948359-96566111-8EC5-4D63-BA07-56077C0ED48CQ62588596-13537980-3BC7-4654-A114-0B99BF6452E3Q79762016-44A7AB1D-5407-4CED-BAC2-9AC06B2230E0Q80572083-BEEBC2FA-5ACA-495A-B977-407E15DA39B7Q82683758-B25F1D88-6CE0-46DE-8A04-39D5755A298BQ91900918-3D89B449-BA54-4F35-8084-6D10187FBE54
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Annette Bruchfeld
@ast
Annette Bruchfeld
@en
Annette Bruchfeld
@es
Annette Bruchfeld
@nl
type
label
Annette Bruchfeld
@ast
Annette Bruchfeld
@en
Annette Bruchfeld
@es
Annette Bruchfeld
@nl
prefLabel
Annette Bruchfeld
@ast
Annette Bruchfeld
@en
Annette Bruchfeld
@es
Annette Bruchfeld
@nl
P106
P31
P496
0000-0002-9752-9941